Toprol XL: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
{| style="border: 3px solid #696969;" | {| style="border: 3px solid #696969;" | ||
| style="background: #000000; border: 0px; padding: | | style="background: #000000; border: 0px; padding: 20px 20px; width: 800px;" | | ||
<center> | <center> | ||
<font color="#F8F8FF">'''WARNING'''</font> | <font color="#F8F8FF">'''WARNING'''</font> | ||
| Line 19: | Line 17: | ||
Following abrupt cessation of therapy with beta-blocking agents, exacerbations of angina pectoris and myocardial infarction have occurred. Warn patients against interruption or discontinuation of therapy without the physician’s advice. | Following abrupt cessation of therapy with beta-blocking agents, exacerbations of angina pectoris and myocardial infarction have occurred. Warn patients against interruption or discontinuation of therapy without the physician’s advice. | ||
</font></b> | </font></b> | ||
|} | |} | ||
Revision as of 08:23, 13 March 2014
 | |
| Clinical data | |
|---|---|
| Trade names | Lopressor, Toprol-xl |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682864 |
| [[Regulation of therapeutic goods |Template:Engvar data]] |
|
| Pregnancy category | |
| Routes of administration | Oral, IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 12% |
| Metabolism | Hepatic via CYP2D6, CYP3A4 |
| Elimination half-life | 3-7 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H25NO3 |
| Molar mass | 267.364 g/mol |
| 3D model (JSmol) | |
| Melting point | 120 °C (248 °F) |
| |
| |
| (verify) | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
WARNING See full prescribing information for complete boxed warning.
|